AbL Diagnostics SA (ABLD) - Total Assets
Based on the latest financial reports, AbL Diagnostics SA (ABLD) holds total assets worth €12.95 Million EUR (≈ $15.15 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore AbL Diagnostics SA (ABLD) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
AbL Diagnostics SA - Total Assets Trend (2007–2025)
This chart illustrates how AbL Diagnostics SA's total assets have evolved over time, based on quarterly financial data. See AbL Diagnostics SA (ABLD) shareholders funds for net asset value and shareholders' equity analysis.
AbL Diagnostics SA - Asset Composition Analysis
Current Asset Composition (December 2025)
AbL Diagnostics SA's total assets of €12.95 Million consist of 72.8% current assets and 27.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 8.4% |
| Accounts Receivable | €4.93 Million | 38.0% |
| Inventory | €1.14 Million | 8.8% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €2.94 Million | 22.7% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2007–2025)
This chart illustrates how AbL Diagnostics SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see ABLD stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: AbL Diagnostics SA's current assets represent 72.8% of total assets in 2025, a decrease from 96.3% in 2007.
- Cash Position: Cash and equivalents constituted 8.4% of total assets in 2025, up from 3.9% in 2007.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 22.0% of total assets, an increase from 0.0% in 2007.
- Asset Diversification: The largest asset category is accounts receivable at 38.0% of total assets.
AbL Diagnostics SA Competitors by Total Assets
Key competitors of AbL Diagnostics SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
UNIDOC HEALTH CORP.
F:L7T
|
Germany | €2.30 Million |
|
Pro Medicus Ltd
AU:PME
|
Australia | AU$533.91 Million |
|
Echoiq Ltd
AU:EIQ
|
Australia | AU$17.99 Million |
|
ARTRYA Ltd
AU:AYA
|
Australia | AU$92.19 Million |
|
Cogstate Ltd
AU:CGS
|
Australia | AU$64.77 Million |
|
Oneview Healthcare Plc
AU:ONE
|
Australia | AU$15.49 Million |
|
Alcidion Group Ltd
AU:ALC
|
Australia | AU$115.63 Million |
|
Doctor Care Anywhere Group Plc
AU:DOC
|
Australia | AU$15.02 Million |
AbL Diagnostics SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.41 | 3.01 | 131.37 |
| Quick Ratio | 2.12 | 2.76 | 131.37 |
| Cash Ratio | 0.00 | 0.02 | 130.40 |
| Working Capital | €5.51 Million | €5.63 Million | €2.36 Million |
AbL Diagnostics SA - Advanced Valuation Insights
This section examines the relationship between AbL Diagnostics SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.26 |
| Latest Market Cap to Assets Ratio | 3.18 |
| Asset Growth Rate (YoY) | 9.7% |
| Total Assets | €12.95 Million |
| Market Capitalization | $41.14 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values AbL Diagnostics SA's assets at a significant premium (3.18x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: AbL Diagnostics SA's assets grew by 9.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for AbL Diagnostics SA (2007–2025)
The table below shows the annual total assets of AbL Diagnostics SA from 2007 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €12.95 Million ≈ $15.15 Million |
+9.70% |
| 2024-12-31 | €11.81 Million ≈ $13.81 Million |
-20.76% |
| 2023-12-31 | €14.90 Million ≈ $17.42 Million |
-3.28% |
| 2022-12-31 | €15.41 Million ≈ $18.01 Million |
+467.87% |
| 2021-12-31 | €2.71 Million ≈ $3.17 Million |
+14.04% |
| 2020-12-31 | €2.38 Million ≈ $2.78 Million |
-66.99% |
| 2019-12-31 | €7.21 Million ≈ $8.43 Million |
-6.95% |
| 2018-12-31 | €7.75 Million ≈ $9.06 Million |
+3.21% |
| 2017-12-31 | €7.51 Million ≈ $8.78 Million |
+8.51% |
| 2016-12-31 | €6.92 Million ≈ $8.09 Million |
-6.77% |
| 2015-12-31 | €7.42 Million ≈ $8.67 Million |
+12.97% |
| 2014-12-31 | €6.57 Million ≈ $7.68 Million |
+11.20% |
| 2013-12-31 | €5.91 Million ≈ $6.90 Million |
+11.54% |
| 2012-12-31 | €5.29 Million ≈ $6.19 Million |
+1.66% |
| 2011-12-31 | €5.21 Million ≈ $6.09 Million |
+0.86% |
| 2010-12-31 | €5.16 Million ≈ $6.04 Million |
+1.68% |
| 2009-12-31 | €5.08 Million ≈ $5.94 Million |
+1.18% |
| 2008-12-31 | €5.02 Million ≈ $5.87 Million |
+2.53% |
| 2007-12-31 | €4.90 Million ≈ $5.72 Million |
-- |
About AbL Diagnostics SA
ABL Diagnostics Société anonyme provides proprietary molecular biology assays and end-to-end solutions to be used for molecular detection by polymerase chain reaction (PCR) and through DNA sequencing in France and internationally. The company offers genotyping through NGS and sanger sequencing for human immunodeficiency virus, SARS CoV-2, hepatitis-C virus, mycobacterium tuberculosis, and 16S/18S… Read more